Health care stocks advanced late Friday afternoon, with the NYSE Health Care Index up 0.2% and the Health Care Select Sector SPDR Fund (XLV) adding 1.6%.
The iShares Biotechnology ETF (IBB) climbed 1.5%.
In corporate news, Pfizer (PFE) said the US Food and Drug Administration approved a combination of its Braftovi cancer drug with Eli Lilly's (LLY) Erbitux and three other chemotherapies to treat patients with metastatic colorectal cancer. Pfizer shares rose 2.2%, and Eli Lilly added 2.1%.
RxSight (RXST) shares dropped 11% after Stifel downgraded the company's stock to hold from buy and cut its price target to $40 from $65.
Novo Nordisk (NVO) shares tumbled 17% after clinical trial results of the company's investigative weight loss drug fell short of its own expectations.
Synaptogenix (SNPX) shares jumped 16% after its board formed an independent special committee to explore strategic opportunities, including drug development platforms and new technologies and services.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。